News Trodelvy gets EU nod for first-line triple-neg breast cancer A new EC authorisation expands Gilead's market for triple-negative breast cancer ADC Trodelvy.
News EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe Acadia Pharmaceuticals has secured EC approval for DAYBU (trofinetide) for the neurobehavioural symptoms of Rett syndrome in the EU.
News J&J scores EU approval for Tecvayli combo in second line Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.
News EU first to clear AbbVie's Rinvoq for alopecia areata AbbVie's fast-growing JAK inhibitor Rinvoq has been cleared for alopecia areata in the EU, its first market for the hair loss disorder.
News EU clears AZ's SERD camizestrant, as FDA review drags on AstraZeneca's new breast cancer therapy Etcamah claims landmark frontline approval in the EU, but its prospects in the US are less certain.
News Moderna's mResvia gets shot in the arm from EU contract A new EU procurement contract could give Moderna's RSV shot mResvia, which has struggled to gain traction in the market, a welcome boost.
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
